3 results
Approved WMOCompleted
to determine the normal FGF23 response in case of hypophosphatemia
Approved WMORecruiting
• Randomized Placebo-Controlled Period:Primary:- to demonstrate the efficacy of mavorixafor in patients with Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) syndrome as assessed by increasing levels of circulating neutrophils…
Approved WMOWill not start
To compare the antiproteinuric effects of sacubitril/valsartan (ARNI) and valsartan (ARB).